World Incretin-Based Drugs Market - Opportunities and Forecasts, 2020-2027
A00535 | Pages: NA | Feb 2021 | 2145 Views | | |
Author(s) : NA | Tables: NA | Charts: NA | Formats*: | |
COVID-19
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the World Incretin-based Drugs Market
Request Now !Incretins are gut derived hormones, released after the ingestion of food. Incretins are classified into glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Both the molecules are inactivated by enzyme Dipeptidyl Peptidase-4 (DPP-4). Oral traditional anti-diabetic drugs, often fail to maintain the desired normal level of glucose, especially in the postprandial condition. This has resulted in a strong need for better therapeutics such as incretin based drugs. Incretin not only increases the secretion of insulin by acting on pancreatic beta cells, but also inhibits the release of glucagon by acting on the pancreatic alpha cells. Incretin based drugs namely; Incretin mimetics (GLP-1 agonist) and DPP-4 inhibitors work on the antidiabetic principle of incretin hormone. Incretin based drugs reduce body weight and have better cardiovascular outcomes. The major drivers of global incretin based drugs market are increasing incidence of diabetes, rising old age population, increasing rate of cardiovascular diseases and obesity, sedentary lifestyle and increasing awareness of diabetes. Furthermore, large number of either undiagnosed or pre-diabetic patients across the globe, could further fuel the market growth. However, high cost of treatment, lack of reimbursement, poor accessibility to drugs especially in developing countries, and some safety concerns associated with incretin based drugs, are likely to restrain the market.
The global incretin-based drugs market is segmented on the basis of drug type, formulation, and geography. On the basis of drug type, market is further segmented into Glucagon-like peptide-1 receptor (GLP-1) agonists and Dipeptidyl Peptidase-4 (DPP-4) inhibitors. According to formulation, the market is segmented into oral and injectable drugs. Geographically, the market is segmented across four regions namely North America, Europe, Asia Pacific and LAMEA.Â
New product launches and approvals are the few strategies adopted by top industry players. Recently GlaxoSmithKline has launched subcutaneous injection of Tanzeum (albiglutide), a GLP-1 agonist for treatment for type 2 diabetes. In March 2015, Takeda Pharmaceutical got Japanese approval for oral tablet Zafatek, a DPP-4 inhibitor. The companies profiled in the report include, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Inc., AstraZeneca plc, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company Ltd and Sanofi S.A.
KEY MARKET BENEFITS:
Comprehensive analysis of factors that drive and restrict the growth of the global incretin-based drugs market is provided
The market estimations are made in the report by conducting high-end analysis of the key market segments for the period of 2014‐2020, which would enable the stakeholders to capitalize on prevailing market opportunities
An in-depth analysis of key segments of the market demonstrates the types of drugs and formulations that are currently being used along with the variants that would gain prominence in future
SWOT analysis enables to study the internal environment of the leading companies for strategy formulation
Region-wise incretin-based drugs market conditions are comprehensively analyzed in the report
KEY MARKET SEGMENTS:
The global incretin-based drugs market is segmented below:
Global Incretin Based Drugs Market ‐ By Drug Type
Glucagon-like peptide-1 receptor (GLP-1) agonists
Dipeptidyl Peptidase-4 (DPP-4) inhibitors
Global Incretin Based Drugs Market ‐ By Formulation
Oral Drugs
Injectable Drugs
Global Incretin Based Drugs Market ‐ By Geography
North America
Europe
Asia-Pacific
LAMEA
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
Access from any device, anywhere
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
REQUEST TOC/SAMPLE
Purchase Full Report of
World Incretin-Based Drugs Market-
Opportunities and Forecasts, 2020-2027
- Online Only
-
$3,456$3,110 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Data Pack
-
$3,840$3,456 - Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Single User
-
$5,769$5,192 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Five Users
-
$6,450$5,805 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
-
Enterprise
License/PDF -
$8,995$8,096 - Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
10%
Discount
- Library Membership
- $ 699/mo
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading.
Buy Now
This title and over 12,000+ are available on the Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Featured Reports
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers